Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 45Sarcoma 33Lymphoma, Large B-Cell, Diffuse 32Neoplasms 25Lymphoma 20Lymphoma, Non-Hodgkin 19Ovarian Neoplasms 17Lymphoma, Follicular 16Neoplasm Metastasis 12Triple Negative Breast Neoplasms 11Lymphoma, B-Cell 11Endometrial Neoplasms 11Recurrence 10Carcinoma, Hepatocellular 8Hodgkin Disease 7Lymphoma, T-Cell, Peripheral 6Hematologic Diseases 6Sarcoma, Kaposi 5Lymphoma, Mantle-Cell 5Leiomyosarcoma 5HIV Infections 5Acquired Immunodeficiency Syndrome 5Multiple Myeloma 4Liposarcoma 4Small Cell Lung Carcinoma 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3Fallopian Tube Neoplasms 3

Interventions

trametinib 1spartalizumab 1pembrolizumab 1nazartinib 1canakinumab 1Pemetrexed 1Doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Ductal × Doxorubicin × Clear all
NCT00461344 2008-04-03

Docetaxel + Doxorubicin as Neoadjuvant Chemotherapy in Patients With Breast Cancer

Sanofi

Phase 2 Terminated
20 enrolled

Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡